(A) Hela cells (10cells/well in 12-well plate) were cotransfected with ERE-Luc (0

5 ug), expression vectors for Vav3, Vav3*, or empty vector pHEF (200 ng) and ERα (50 ng), respectively. Then, the cells were treated without or with E2 (10M) and without or with Tamoxifen. (B and C) MCF7 cells (10cells/well in 12-well plate) were cotransfected with ERE-Luc (0.5 ug) (B) or pS2-Luc (0.5 ug) (C), and expression vector (0.25 ug) for Vav3*, or empty vector pHEF, respectively. Then, the cells were treated with E2. All transfection and drug treatment are in stripped medium for 24 hours, followed by luciferase assay. Renilla luciferase as an internal control was used to normalize the data. Data are presented as the mean (± SD) of duplicate values of a representative experiment that was independently repeated for five times.<p><b>Copyright information:</b></p><p>Taken from "Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer"</p><p>http://www.biomedcentral.com/1471-2407/8/158</p><p>BMC Cancer 2008;8():158-158.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2430719.</p><p>